Innovators & Thought Leaders To Convene At Powering Precision Health Summit 2017

By Kevin Hrusovsky, Executive Chairman And CEO, Quanterix

There was a thrilling energy in the air at last year’s Powering Precision Health Summit (PPHS) – a feeling that could only come from the sense of community and empowerment we experienced at the inaugural event. As the world’s first innovation-driven summit dedicated to transforming precision health, PPHS brought together key stakeholders across the healthcare community, including physicians, scientists, innovators, biopharma executives, patients and patient advocates, to tackle the world’s most pressing issues, as we move forward on the path to turn today’s reactive sick care into tomorrow’s preventative health care.

In continuance of its mission to establish a new paradigm for precision health, this year’s event, themed Prevent. Detect. Treat. Powering Precision Health, will once again bring together the industry’s most innovative and passionate stakeholders to share research, ideas, and innovations, at a pivotal time for biomarker research and translational medicine. Building on the success of last year’s conference, which not only assembled a dynamic group of leaders but also helped mobilize a precision medicine movement, we hope to once again bring forth new insights and advances across four core therapeutic areas – cardiology, oncology, neurology, and infectious disease, as well as advance the discussion around digital health.  

Groundbreaking Research & Industry Insight

Serving once again as a forum for the latest research revolutionizing precision health care, attendees will have the pleasure of hearing from a number of leading scientists, who are at the forefront of biomarker research, including:

  • Gordon J. Freeman, Ph.D., Dana Farber Cancer Institute and Professor of Medicine, Harvard Medical School
  • Charles H Tator, Ph.D., MD, Emeritus Scientist, Krembil Research Institute
  • Rudy Tanzi, Ph.D., Vice-Chair of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital
  • Jessica M. Gill, Ph.D, RN, Investigator at National Institutes of Health (NIH)
  • John Houston, Ph.D., CSO and President of R&D, Arvinas, Former SVP Bristol-Myers Squibb, Microbial Biochemistry
  • Petr Jarolim, MD,Ph.D, Medical Director, Clinical Chemistry, Laboratory Control, and Ambulatory Care Center Clinical Laboratories, Brigham and Women’s Hospital and Associate Professor, Harvard Medical School
  • Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School
  • Robert Stern, Ph.D., professor of Neurology, Neurosurgery, and Anatomy and Neurobiology at Boston University School of Medicine and Director of the Clinical Core of the Boston University Alzheimer’s Disease and CTE Center
  • Russell Lonser, MD, Professor and Chair, Department of Neurological Surgery, The Ohio State University Wexner Medical Center
  • Henrik Zetterberg, Ph.D., professor of Neurochemistry at the University of Gothenburg, Sweden.

In addition to unveiling new research poised to transform how diseases are detected and treated, participants will hear from life science experts and executives at today’s leading medical technology companies, which are striving to bring new approaches to prevention, early diagnosis and next-generation treatment to market through digital health solutions. These include:

Fresh Perspectives on Head Health

While PPHS 2017 will offer a range of track options across the aforementioned therapeutic categories, neurology will once again be a focus area. Traumatic brain injuries (TBIs) continue to pose a serious risk and remain challenging to diagnose. Although the long-term impact of head hits are still being understood, we’re now seeing more evidence of the linkage between repeated head injuries and neurodegenerative diseases, such as Parkinson’s, Alzheimer’s and Chronic traumatic encephalopathy (CTE)

In addition to hearing from principal researchers in this field, PPHS will bring new viewpoints from outside of the research realm to the discussion, including:

  • Chris Nowinski, co-founder and executive director of Concussion Legacy Foundation and former professional wrestler with World Wrestling Entertainment (WWE)
  • Jerod Mayo, former New England Patriot Linebacker. Currently Comcast Quick Slants co-host and Executive in Residence Optum Health
  • Chris Borland, former San Francisco 49ers Linebacker

Attendees will hear firsthand how head health concerns have impacted players and how organizations, such as the Concussion Legacy Foundation, are working toward better detection and treatment methods for concussions and other forms of TBI.

We hope you’ll join us on October 24-25, 2017 in Cambridge, Massachusetts for what’s sure to be another transformational summit. To learn more about the event and see our current (and growing) list of speakers, visit To register, click here.